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ABSTRACT
We inserted the sequence of the carcinoembryonic antigen-derived T cell epitope CAP-1-6D (CEA)
into different positions of the hamster polyomavirus major capsid protein VP1. Independently from
additional flanking linkers, yeast-expressed VP1 proteins harboring the CEA insertion between VP1
amino acid residues 80 and 89 (site 1) or 288 and 295 (site 4) or simultaneously at both positions
assembled to chimeric virus-like particles (VLPs). BALB/c mice immunized with adjuvant-free VLPs
developed VP1- and epitope-specific antibodies. The level of the CEA-specific antibody response was
determined by the insertion site, the number of inserts, and the flanking linker. The strongest CEA-
specific antibody response was observed in mice immunized with VP1 proteins harboring the CEA
insert at site 1. Moreover, the CEA-specific antibodies in these mice were still detectable 6 mo af-
ter the final booster immunization. Our results indicate that hamster polyomavirus-derived VLPs
represent a highly immunogenic carrier for foreign insertions that might be useful for clinical and
therapeutic applications.
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INTRODUCTION
VIRUS-LIKE PARTICLES (VLPs) produced by heterolo-gous synthesis of viral structural proteins resemble
native infectious virions in their structural and immuno-
logical properties, but are noninfectious because they lack
viral nucleic acid. The strong immunogenicity of VLPs
is reflected not only in the induction of antibody but also
helper T and cytotoxic T lymphocyte (CTL) responses.
Therefore, VLPs have become promising vaccine candi-
dates against a large number of human and animal virus
infections. Thus VLPs based on hepatitis B virus and hu-
man papillomavirus antigens are already in use in hu-
mans as recombinant vaccines. The advantageous im-
munological properties of VLPs can also be transferred
to foreign peptides or protein segments presented on the
surface of so-called chimeric VLPs (for review see
Pumpens and Grens [13]).
Although the capsid of polyomaviruses consists of the
major capsid protein VP1, the minor capsid proteins VP2
and VP3 and the viral double-stranded DNA, poly-
omavirus-derived VLPs have been generated by heterol-
ogous synthesis of VP1 alone. Expression of VP1 origi-
nating from human polyomaviruses JC and BK, murine
polyomavirus (MPyV), and other mammalian and avian
polyomaviruses in insect and yeast cells resulted in the
formation of VLPs (see Sasnauskas et al. [16] and Te-
gerstedt et al. [19]). Escherichia coli-expressed VP1 pen-
tamers of MPyV and avian polyomavirus were demon-
strated to assemble to VLPs in vitro (14,15).
The entire VP1 and an amino-terminal extended de-
rivative of hamster polyomavirus (HaPyV) expressed in
E. coli, yeast Saccharomyces cerevisiae, and insect cells
spontaneously formed VLPs (17,23). Carboxy-terminal
truncation of 21, 69, and 79 amino acid residues from
yeast-expressed HaPyV-VP1 also allowed the formation
of VLPs resembling the electron microscopic image of
authentic VLPs (5). A single insertion of a 5-amino acid-
long foreign peptide at site 1 (between amino acids 80
and 89), 2 (between amino acids 222 and 225), 3 (be-
tween amino acids 243 and 247), or 4 (between amino
acids 288 and 295) confirmed their predicted flexibility
and surface exposure on VP1 (7). Scanning of these four
predicted surface-exposed regions with 45- and 120-
amino acid-long foreign protein segments confirmed sites
1 and 4 as preferential insertion sites for longer foreign
protein segments (8). The peptides and protein segments
presented on VLPs were demonstrated to induce a strong
antibody and T cell response in mice, even when applied
without additional adjuvant (7,8).
Recombinant polyomavirus-derived VLPs are promis-
ing tools for virus diagnostics and seroepidemiological
studies (18,25) as well as gene therapy and vaccine de-
velopment (3,20). HaPyV-VP1-derived VLPs have been
demonstrated to represent a useful tool for the generation
of monoclonal antibodies (mAbs) of desired epitope
specificity (26). This conclusion was based on an ap-
proach with VLPs harboring two copies of a CTL epi-
tope originating from human mucin 1 protein (VP1/1,4L-
MUC1). To generate MUC1-specific antibodies, mice
were immunized with VP1/1,4L-MUC1 VLPs, using 
Freund’s complete adjuvant for primary immunization.
Therefore, the objectives of the present study were to
prove a potential optimization of this system by investi-
gating the influence of the insertion site, the number of
foreign inserts, and the additional insertion of a flexible
linker on the assembly capacity of VP1 fusion proteins
and their immunogenicity in mice. As a model epitope
for these investigations the nonamer peptide sequence
CAP-1-6D (in the following, CEA [24]) was selected.
This T cell peptide is derived from the carcinoembryonic
antigen, which is expressed in high concentration in sev-
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eral epithelial tumors and represents a target for im-
munotherapy (9).
MATERIALS AND METHODS
Generation of VP1 expression plasmids
The generation of plasmids pVP1-1, pVP1-2, pVP1-3,
and pVP1-4 allowing insertions into the VP1-encoding
sequence at sites 1, 2, 3, and 4, respectively, was de-
scribed previously (7). Novel expression vectors were
generated by modifying sites 1, 2, 3, and 4 in these plas-
mids by introduction of Gly-Ser-Ser-Gly-encoding link-
ers on both sides of the BglII insertion site (see Fig. 1A).
An oligonucleotide duplex encoding the 9-amino acid-
long CEA peptide was generated by hybridization of
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FIG. 1. Schematic presentation of the VP1 proteins har-
boring carcinoembryonic antigen-derived peptide CAP-1-6D
(CEA) at various insertion sites. The unique BglII insertion site
in the VP1-encoding sequence was modified by insertion of a
linker sequence (A). The CEA peptide-encoding sequence was
generated as an oligonucleotide duplex (B). The CEA-encod-
ing duplex was inserted into sites 1 and 4 of the nonmodified
or into sites 1, 2, 3, and 4 of the linker-bearing VP1-encoding
sequence (C).
oligonucleotides CEA-5 and CEA-3, purchased from
Metabion (Martinsried, Germany; Fig. 1B). This oligonu-
cleotide duplex was inserted into the VP1-encoding se-
quence at various positions, resulting in seven VP1/CEA
fusion-encoding constructs (Fig. 1C).
Finally, these chimeric VP1 protein-encoding se-
quences were confirmed by DNA sequence analysis and
subsequently subcloned into the unique XbaI site of the
yeast expression vector pFX7 (17).
Expression and purification of VP1 
fusion proteins
The pFX7-derived yeast expression plasmids and con-
trol plasmid pFX7-VP1/2-12 encoding the authentic
HaPyV-VP1 (17) were transformed into S. cerevisiae
strain AH22-214 (MATa leu2 his4). Cultivation of yeast
cells and protein expression and purification were per-
formed as previously described (7). All purified proteins
were dialyzed against phosphate-buffered saline (PBS),
lyophilized, and stored at 20°C until further use.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and immunoblot analysis
Crude yeast lysates or cesium chloride (CsCl) gradi-
ent fractions were separated in a sodium dodecyl sulfate
(SDS)–12.5% polyacrylamide gel and stained with
Coomassie Brilliant Blue or blotted onto a nitrocellulose
membrane (PROTRAN NC BA3; Schleicher & Schuell,
Dassel, Germany) by a semidry procedure. The mem-
brane was blocked overnight with PBS–5% neonatal calf
serum (NCS) and incubated with VP1-specific mAbs
6D11, 3D10, and 9F11 (26), diluted in PBS–NCS to a fi-
nal concentration of about 1 g/mL, or with polyclonal
mouse serum raised against native carcinoembryonic
antigen (11), diluted to 1:400, for 1 h at room tempera-
ture. After washing twice with PBS–0.5% Tween 20
(PBST), the membrane was incubated with horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG (di-
luted 1:10,000 in PBS–NCS; Dianova, Hamburg, Ger-
many) for 1 h at room temperature. The membrane was
washed three times with PBST and stained with di-
aminobenzidine (DAB [0.8 mg/mL], NiCl2 [0.4 mg/mL],
and 0.01% H2O2 in 100 mM Tris-HCl [pH 7.5]) accord-
ing to standard protocols.
As molecular mass marker the PageRuler prestained
protein ladder (SM0671; Fermentas, Vilnius, Lithuania)
was used.
Electron microscopy
Diluted suspensions from CsCl gradient fractions af-
ter ultracentrifugation were placed on 400-mesh Piolo-
form-covered and carbon-coated copper grids. The sam-
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ples were negatively stained with 1% aqueous uranyl ac-
etate solution and examined with a Zeiss CEM 902 elec-
tron microscope.
Immunizations
Three 6-mo-old BALB/c mice in each group were in-
traperitoneally immunized with 100 g of the VP1/CEA
constructs in 150 L of PBS without any adjuvant. Six
weeks later, this immunization was repeated with the
same amount of the corresponding VP1/CEA constructs,
respectively. Another 7 d later, blood was taken from the
retro-orbital sinus of each mouse and the serum was
checked for the appearance of antibodies against VP1 and
the inserted peptide. For analysis of the long-lasting im-
munity serum samples were taken 6 mo after the final
booster immunization.
Enzyme-linked immunosorbent assay
The CEA peptide (CAP-1-6D; amino acid sequence
YLSGADLNL) was conjugated to bovine serum albumin
(BSA) by the glutardialdehyde method (10). For indirect
enzyme-linked immunosorbent assay (ELISA), microtiter
plates (Greiner, Frickenhausen, Germany) were coated
overnight with 5 g of VP1, BSA, or CEA peptide con-
jugated to BSA, in PBS. After blocking with 3% BSA,
mouse sera, diluted from 1:300 to 1:218,000 for VP1 and
to 1:9600 for CEA peptide and BSA in 3% BSA, were ap-
plied to the plate for 60 min at room temperature. The wells
were washed with tap water and incubated with HRP-
conjugated rabbit anti-mouse immunoglobulin (Dako,
Glostrup, Denmark) for 60 min. After extensive washing
with tap water, color development was achieved with sub-
strate solution containing tetramethyl benzidine (TMB)
and urea-conjugated hydrogen peroxide in sodium dihy-
drogen phosphate buffer, pH 5.6. The reaction was stopped
with 50 L of 1 M H2SO4 and optical densities were mea-
sured at 450 nm with a microplate reader.
RESULTS
Generation of VP1/CEA fusion proteins
For expression in S. cerevisiae, seven different pFX7-
derived constructs encoding VP1 fusion proteins with
CEA (CAP-1-6D) inserts were generated (Fig. 1C). After
cultivation and induction of foreign protein synthesis,
yeast lysates were generated and subjected to sucrose
cushion ultracentrifugation and subsequent twice CsCl
gradient centrifugation. SDS–PAGE analysis of CsCl gra-
dient fractions revealed for all constructs the presence 
of full-length VP1 fusion proteins (Fig. 2A, lanes 1–7)
larger than the original VP1 (Fig. 2A, lane 8; about 42
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kDa). In general, the observed migration of the fusion pro-
teins corresponded to the respective predicted molecular
masses. However, the observed molecular masses of 
the linker-containing VP1/CEA fusion proteins, and of
VP1/1,2,3,4L-CEA in particular, were much larger than
expected, most likely reflecting yeast-mediated post-
translational modifications of the recombinant proteins.
All fusion proteins, except VP1/1,2,3,4L-CEA, resembled
VP1 in their quantity and purity in SDS–PAGE after sec-
ond CsCl gradient purification. Smaller defined degrada-
tion products were observed exclusively in fractions of
VP1/1L-CEA, VP1/4L-CEA, and VP1/1,4L-CEA (Fig.
2A, lanes 2, 4, and 6; labeled with an asterisk).
Antigenic characterization of VP1/CEA 
fusion proteins
Immunoblot analysis confirmed the expression of VP1
derivatives by specific reaction with VP1-specific mAb
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6D11 (Fig. 2B) and with mAbs 3D10 and 9F11 (data not
shown) for all constructs tested, except VP1/1,2,3,4L-
CEA. In line with our previous epitope mapping data (26),
this fusion protein was detected by mAbs 6D11 and 3D10,
but failed to react with mAb 9F11 because of the destruc-
tion of its binding site (amino acids 223/224) by CEA in-
sertion. Thus, all full-sized VP1 fusion proteins contain an
intact amino terminus with amino acids 1–64 and amino
acids 59–152 of VP1 representing the epitope regions of
mAbs 6D11 and 3D10, respectively (26). The full-sized
VP1/CEA fusion proteins were also detected by a mouse
serum raised against native carcinoembryonic antigen (Fig.
2C). The observed low reactivity might be due to the short
segment of carcinoembryonic antigen presented on VLPs
as well as differences in the amino acid sequence and post-
translational modifications of the CEA peptide used here
and that of the native carcinoembryonic antigen used for
the generation of the polyclonal antiserum. The degrada-
tion products observed in the SDS–PAGE for VP1/1L-
CEA, VP1/4L-CEA, and VP1/1,4L-CEA were found to be
reactive with mAb 9F11 (data not shown). This leads to
the conclusion that these VP1-derived smaller protein
bands resulted from degradation processes most likely in-
duced by linker insertion. Additional immunoblot data
demonstrated differences in their antigenicity; the smaller
derivatives of VP1/4L-CEA (about 30 kDa) and VP1/1,4L-
CEA (about 36 kDa) were recognized by mAbs 6D11 (Fig.
2B, lanes 4 and 6, respectively) and 3D10 (data not shown),
whereas the VP1/1L-CEA product (about 35 kDa) failed
to react with both mAbs (Fig. 2B, lane 2; and data not
shown). In contrast to this lack of reactivity of the smaller
product of VP1/1L-CEA with anti-VP1 antibodies, it was
detected by the mouse serum raised against native carci-
noembryonic antigen (Fig. 2C, lane 2). As the epitopes of
both mAbs are located in the amino-terminal region of
VP1, the larger fragment of VP1/1L-CEA is lacking the
amino-terminal part, probably close to the position of the
first insertion site at amino acid 80. These data imply that
the region spanning amino acids 59–80 may represent an
essential part of the epitope region of mAb 3D10.
Analysis of the assembly capacity of VP1/CEA
fusion proteins
The major peak of VP1 antigenicity was recovered for
almost all VP1/CEA fusion proteins in a fraction of the
final CsCl density gradient where wild-type VP1 was
found. This migration behavior of almost all VP1/CEA
fusion proteins suggested the formation of chimeric
VLPs. The VP1/1,2,3,4L-CEA fusion protein was the
only protein recovered in a CsCl gradient fraction of
lower density (data not shown). Negative stain electron
microscopy confirmed the assembly of VLPs for almost
all VP1/CEA fusion proteins (Fig. 3A–F). All VLPs were
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FIG. 2. Detection of VP1/CEA fusion proteins after cesium
chloride density gradient centrifugation by SDS–PAGE (A) and
immunoblot analysis using VP1-specific monoclonal antibody
6D11 (B) and polyclonal mouse serum raised against native car-
cinoembryonic antigen (C). Aliquots of gradient fractions from
yeast cells expressing VP1/1-CEA (lane 1), VP1/1L-CEA (lane
2), VP1/4-CEA (lane 3), VP1/4L-CEA (lane 4), VP1/1,4-CEA
(lane 5), VP1/1,4L-CEA (lane 6), VP1/1,2,3,4L-CEA (lane 7),
and wild-type VP1 (lane 8) were applied to a 12.5% SDS–poly-
acrylamide gel. Full-sized fusion proteins are marked by ar-
rowheads and shorter degradation products are indicated by as-
terisks.
found to correspond in shape and size to that of authen-
tic VP1 (Fig. 3H). These investigations revealed no 
obvious differences in assembly between constructs 
harboring one or two CEA insertions, irrespectively of 
a flanking linker. Although SDS–PAGE and im-
munoblot analysis have proven the synthesis and suc-
cessful purification of VP1/1,2,3,4L-CEA protein, elec-
tron microscopy failed to detect the formation of VLPs
(Fig. 3G).
Antibody response of mice against VLPs applied
without adjuvant
Three mice of each group were immunized intraperi-
toneally with VP1/CEA fusion proteins or VP1 alone (see
Table 1) and boosted after 6 wk with the same amount
of protein. There was no adjuvant administered at any
time of immunization. Seven days after the boost, blood
was taken and samples were screened by indirect ELISA
for VP1, BSA, or CEA peptide conjugated to BSA.
With the exception of the group immunized with
VP1/1,2,3,4L-CEA, in sera from mice of all other groups
immunized with chimeric VLPs, CEA-specific antibod-
ies were detected by their reactivity with BSA-coupled
CAP1-6D peptide (Table 1). In the groups immunized
with VP1/1-CEA, VP1/1L-CEA, and VP1/1,4L-CEA all
mice developed CEA-reactive antibodies. In contrast, in
the groups immunized with VP1/4-CEA, VP1/4L-CEA,
and VP1/1,4-CEA only two or one of three mice showed
an CEA-specific antibody response. Furthermore, the av-
erage of the titer in the groups immunized with VP1/1-
CEA and VP1/1L-CEA was higher than that observed in
the other groups. Whereas the linker addition influenced
the immunogenicity of the insert for these constructs only
slightly, its employment drastically improved the im-
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munogenicity of the construct harboring two CEA inser-
tions. The lack of reactivity of sera from mice immunized
with VP1 alone confirmed the specificity of the CAP1-
6D ELISA (Table 1).
All mice immunized with VP1-derived VLPs devel-
oped VP1-specific antibodies, except those immunized
with VP1/1,2,3,4L-CEA (Table 1). In comparison with
wild-type VP1, all VP1 responses induced by VP1/CEA
VLPs were decreased. The immunization of mice with
linker-bearing constructs resulted in higher titers of VP1-
specific antibodies. In addition, the anti-VP1 responses
of mice immunized with fusion proteins with only one
insert were superior to those with two inserts.
To prove the induction of long-lasting immunity, sera
from mice immunized with the most immunogenic VLPs
(VP1/1-CEA, VP1/1L-CEA, and VP1/1,4L-CEA) were
taken 6 mo after the final booster immunization and tested
for VP1- and CEA-specific antibodies (Table 1). All mice
immunized with chimeric VLPs demonstrated the pres-
ence of CEA-specific antibodies with the highest titer be-
ing found in animals immunized with VP1/1-CEA VLPs.
In these animals the levels of the titers of anti-CEA and
anti-VP1 antibodies after 6 mo were only moderately re-
duced compared with the titers of antibodies analyzed 
1 wk after the final booster immunization. The reduction
of the titers of CEA- and VP1-specific antibodies in the
animals immunized with VP1/1L-CEA and VP1/1,4L-
CEA was larger.
DISCUSSION
The assembly capacity of a VLP carrier system and the
immunogenicity of a foreign epitope presented on these
VLPs can be influenced by the number and length of in-
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FIG. 3. Electron micrographs of gradient-purified fusion proteins VP1/1-CEA (A), VP1/1L-CEA (B), VP1/4-CEA (C),
VP1/4L-CEA (D), VP1/1,4-CEA (E), VP1/1,4L-CEA (F), VP1/1,2,3,4L-CEA (G), and wild-type VP1 control (H).
serts, and their position in the carrier moiety and its sur-
rounding region. The HaPyV-VP1 carrier was previously
demonstrated to have a large insertion capacity for foreign
sequences (8). Site 4 of HaPyV-VP1 even tolerated the in-
sertion of an enhanced green fluorescent protein (6). Short-
sized epitopes (five amino acids in length) can be inserted
as single copies into various sites of VP1 or simultane-
ously into sites 1 and 2 or sites 1 and 3 without disturb-
ing the formation of chimeric VLPs (7). The investiga-
tions presented here confirmed the high insertion capacity
of HaPyV-VP1 and its potential to tolerate a simultane-
ous insertion of epitopes into various sites of the same
VP1 molecule, thereby increasing the epitope copy num-
ber per VLP. In line with data on a VP1/1,2,3,4L-MUC1
fusion protein (our unpublished data), the lack of assem-
bly capacity of the VP1/1,2,3,4L-CEA fusion protein
demonstrated limitations of the assembly capacity of
HaPyV-VP1. Similarly, larger insertions into sites 2 and
3 resulted in an inefficient formation of VLPs (8).
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Our findings imply that the position of an insert along-
side the correct assembly of VLPs plays a major role in
its immunogenic potential. The strongest CEA-specific
antibody response was observed in mice immunized with
VP1 proteins harboring the CEA insert at site 1. This
strong antibody response seems not to be influenced by
additional linker insertion, suggesting a highly flexible
property of the insert at this site. This observation is in
line with our previous data for a five-amino acid-long in-
sert (7). In contrast, the immunogenicity of 45- and 120-
amino acid-long inserts was found to be almost the same
for insertion sites 1 and 4 (8). Although the linker also
did not influence the immunogenicity of the CEA insert
in position 4, it obviously improved the immunogenicity
of the VP1 fusion harboring two copies of the CEA epi-
tope. These findings assert the prediction that the linker
contributes to a better integration of the inserts in the pro-
tein, thus keeping the VP1 structure intact.
Although in general it is assumed that the epitope den-
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TABLE 1. ELISA REACTIVITY OF SERA FROM MICE IMMUNIZED WITH CHIMERIC VP1/CEA 
VLPS 1 WEEK AND 6 MONTHS AFTER FINAL BOOSTER IMMUNIZATION
Antigen used for Animal
immunization number 1 wk 6 mo 1 wk 6 mo
VP1/1-CEA 1 24,300 20,000 2,400 2,000
2 8,100 n.d. 2,400 n.d.
3 24,300 20,000 9,600 3,000
VP1/1L-CEA 4 24,300 10,000 4,800 600
5 24,300 10,000 600 300
6 72,900 20,000 4,800 600
VP1/4-CEA 7 2,700 n.d. 300 n.d.
8 8,100 n.d. 2,400 n.d.
9 8,100 n.d. 1,200 n.d.
VP1/4L-CEA 10 8,100 n.d. 300 n.d.
11 24,300 n.d. 600 n.d.
12 72,900 n.d. 2,400 n.d.
VP1/1,4-CEA 13 2,700 n.d. 300 n.d.
14 8,100 n.d. 300 n.d.
15 900 n.d. 300 n.d.
VP1/1,4L-CEA 16 24,300 5,000 1,200 300
17 24,300 5,000 1,200 300
18 24,300 5,000 2,400 300
VP1/1,2,3,4L-CEA 19 100 n.d. 300 n.d.
20 100 n.d. 300 n.d.
21 100 n.d. 300 n.d.
VP1 22 72,900 10,000 300 300
23 72,900 10,000 300 300
24 24,300 n.d. 300 n.d.
Abbreviation: n.d., not determined.
aGiven are the reciprocal titers where an OD of 0.4 was observed.
VP1 CAP1-6D-BSA
ELISA end-point titersa for
sity may increase the level of an antibody response, the
strong immunogenicity seems to be driven mainly by 
the particulate structure of the antigen. Thus, the VP1/
1,2,3,4L-CEA fusion protein, in spite of its multiple rep-
etitions of the peptide in its structure, did not yield CAP1-
6D-specific antibodies. This may be because the struc-
ture is heavily modified and no assembly is possible as
shown by electron microscopy. Therefore, the presence
of intact assembled virus-like particles is necessary to
generate an immune response, at least when protein is
administered without adjuvant.
The studies presented here demonstrate that HaPyV-
VP1-derived VLPs can replace the effect of an adjuvant
generally necessary when immunizing with an isolated
antigen. This is in line with our previous data on chimeric
HaPyV-VP1 VLPs harboring 45-, 80-, and 120-amino
acid-long segments of a hantavirus nucleocapsid protein
(8). This adjuvant effect has also been demonstrated for
VLPs of other origin (1,4). It is assumed today that an
adjuvant activates the first steps in a response against a
foreign substance, that is, the activation of an antigen-
presenting cell that then activates T cells. Similar events
are initiated when an infectious agent is entering a ver-
tebrate organism. Such foreign and potentially dangerous
agents contain pathogen-associated molecular patterns
(PAMPs) that are recognized by pattern-recognizing re-
ceptors (e.g., Toll-like receptors [TLRs]). Studies on
MPyV and MPyV-derived VLPs suggested a role for
TLR-2 and TLR-4 in the induction of innate immune re-
sponses and tumor susceptibility/resistance of various
mouse strains (22).
VLPs represent promising vaccine candidates for ap-
plication in humans. Thus, VLPs of different origin are
able to induce maturation of human monocyte-derived
dendritic cells (DCs) and strong T cell immunity that is
mediated by cross-presentation (2,12,21). VP1-derived
VLPs of HaPyV and MPyV were demonstrated in vitro
to induce maturation of human DCs and the induction of
a CD8-positive CTL response in vitro (6). This im-
munogenic potential was also transferred to a MUC1-
CTL epitope presented on HaPyV-VP1-derived VLPs
(D.C. Dorn, personal communication). The long-lasting
immunity observed in this paper for mice immunized
with VP1/1-CEA VLPs confirmed the unique immuno-
genic properties of the HaPyV-VP1-derived VLP carrier.
In conclusion, we found position 1 in HaPyV-VP1 to
be the most promising site for insertion of a short im-
munogenic peptide resulting in the induction of a strong
and long-lasting antibody response. The use of a linker
is valuable to preserve the native VP1 structure; it does
not, however, play a role in boosting the immunogenic-
ity for single-insert fusion proteins. The linker can help
to reassemble the VP1 structure for VLPs with multiple
inserts. The investigations confirmed the importance of
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the VP1 structure being intact and assembly taking place
for the immunogenicity of inserted peptides. Because the
VLPs used in these studies have been successfully used
for many different antigens they provide a good candi-
date for use as a general vehicle for adjuvant-free im-
munization of humans and other vertebrates against a
wide variety of antigens.
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